Evidence Hub

The efficacy and safety of oral tofacitinib in oral erosive lichen planus: a case series

Shreya K. Gowda, Vishal Thakur, B. Behera, Sonika Garg, D. K. Sahu, M. Sethy, P. Ayyanar

International Journal of Dermatology, 2024

8 citations

Abstract

various theories on the pathogenesis of OLP; however, activation of T lymphocytes through the JAK2-STAT1-dependent INF-c pathway plays a significant role, and this was demonstrated by Shao et al. in vitro using JAK 1/2 inhibitor baricitinib, which prevents keratinocyte damage by CD8 + T lymphocytes. 4 Although there are many reports on using tofacitinib in lichen planopilaris and cutaneous LP, there are only a few case reports that showed good response to oral JAK inhibitors in recalcitrant erosive OLP in patients who failed to respond to prednisone, acitretin, methotrexate, mycophenolate mofetil, and cyclosporine. 3 Another case report where baricitinib was used for alopecia areata demonstrated a good response in atrophic OLP. 5 Our data depict that tofacitinib can be a promising agent in erosive OLP with no adverse effects, while the data on relapse after discontinuation of therapy was not assessed. Future studies are needed to confirm the efficacy, safety, and relapse rate following the use of tofacitinib in erosive OLP.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free